Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study
- Eric Jeziorski; Antoine Ouziel; Marie Cotillon; Constance Bridonneau; Etienne Bizot; Clément Basse
Access Resources
About
This study looks at the impact of nirsevimab, a monoclonal antibody, on infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis. It describes how immunized infants had fewer hospitalizations and less severe symptoms compared to non-immunized ones. The research was conducted in France and involved 1085 infants under 12 months old. Nirsevimab showed high effectiveness in reducing RSV-related hospital stays by one day and lowering the need for oxygen support. The study suggests that using nirsevimab could lead to significant health benefits and cost savings by preventing severe RSV cases in young children.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.